TargetBeta
AXL
AXL receptor tyrosine kinase · also UFO, JTK11, Tyro7, ARK · Fibronectin type III domain containing
5 programs in company-led studies act on AXL, from 5 companies: 4 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| zanzalintinibrule | Exelixis | phase 3 | 1715 running | KDR, MET | NCIt |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | Beijing Konruns Pharmaceutical | phase 3 | 76 running | FLT3, KDR | NCIt |
| gilteritinibrule | Astellas Pharma | phase 3 | 202 running | ALK, FLT3, LTK | NCIt |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 82 running | MET | the company's pipeline |
| adrixetinibrule | Qurient | phase 2 | 32 running | CSF1R | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Adenoma, Islet Cell, 1 program
- Bronchiolitis Obliterans Syndrome, 1 program
- Carcinoma, Renal Cell, 1 program
- Colorectal Neoplasms, 1 program
- Esophageal Neoplasms, 1 program
- Esophageal Squamous Cell Carcinoma, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Neoplasm Metastasis, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 15, 2026zanzalintinib · Exelixis · phase 3 · NCT05678673
- Dec 30, 2026AXL/FLT3/VEGFR2 Inhibitor KC1036 · Beijing Konruns Pharmaceutical · phase 3 · NCT06194734
- Jan 2027vilzemetkib · Sino Biopharmaceutical · phase 3 · NCT06860971
- Dec 30, 2027adrixetinib · Qurient · phase 2 · NCT05438420
- Jul 31, 2028gilteritinib · Astellas Pharma · phase 3 · NCT05520567
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.